These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 21323538)

  • 21. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
    Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
    BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 23. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
    Bhat P; Bhat JG
    Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
    [No Abstract]   [Full Text] [Related]  

  • 24. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
    Nissenson AR; Mayne TJ; Krishnan M
    Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
    [No Abstract]   [Full Text] [Related]  

  • 25. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
    Lowrie EG; Hampers CL
    N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A lesson from the EPO mess: stop the cost shifting.
    Amerling R
    Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
    [No Abstract]   [Full Text] [Related]  

  • 27. Surviving change: Can the ESRD provisions in the SCHIP create a level playing field?
    Gardner AV
    Nephrol News Issues; 2007 Sep; 21(10):52-3. PubMed ID: 17918480
    [No Abstract]   [Full Text] [Related]  

  • 28. Medicare's ESRD Program, Part 1: Dialysis.
    Long HW
    Physician Exec; 1989; 15(2):24-6. PubMed ID: 10313034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents.
    Swaminathan S; Mor V; Mehrotra R; Trivedi AN
    Health Serv Res; 2015 Jun; 50(3):790-808. PubMed ID: 25355431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization.
    Johnson DS; Meyer KB; Johnson HK
    Am J Kidney Dis; 2011 Apr; 57(4):553-5. PubMed ID: 21333427
    [No Abstract]   [Full Text] [Related]  

  • 31. Medicare programs: changes to the end-stage renal disease prospective payment system transition budget-neutrality adjustment. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Apr; 76(66):18930-4. PubMed ID: 21491804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What can we expect down the road?
    Sullivan J
    Nephrol News Issues; 2011 Apr; 25(4):28-9. PubMed ID: 21542511
    [No Abstract]   [Full Text] [Related]  

  • 33. A quarter century of medicare expenditures for ESRD.
    Eggers PW
    Semin Nephrol; 2000 Nov; 20(6):516-22. PubMed ID: 11111852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Important legal, regulatory issues impacting renal care in 2008.
    Riley J; Pristave R
    Nephrol News Issues; 2008 Dec; 22(13):48-9. PubMed ID: 19149317
    [No Abstract]   [Full Text] [Related]  

  • 35. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
    Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
    BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia: dialysis patients experiences.
    Schatell D; Witten B
    Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
    [No Abstract]   [Full Text] [Related]  

  • 37. Understanding financial risk models: Implicationsfor nephrology practices and dialysis centers.
    Cellini GL
    Nephrol News Issues; 2016 Mar; 30(3):26-8, 30-3. PubMed ID: 27169216
    [No Abstract]   [Full Text] [Related]  

  • 38. What can we learn from the U.S. expanded end-stage renal disease bundle?
    Chambers JD; Weiner DE; Bliss SK; Neumann PJ
    Health Policy; 2013 May; 110(2-3):164-71. PubMed ID: 23419419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the bundle leading to a tighter provider market? Key acquisition, merger mark activity in 2010-2011.
    Neumann ME
    Nephrol News Issues; 2011 Jul; 25(8):32-3. PubMed ID: 21877623
    [No Abstract]   [Full Text] [Related]  

  • 40. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.